David Ricks highlights that oral peptide GLP-1s achieve only about 1% bioavailability due to gut acid breakdown, requiring bioprocess manufacturing. In contrast, chemically derived small molecules like Lilly's achieve 50% to 80% bioavailability. While synthesizing a GPCR agonist chemically without off-target effects is technically difficult, chemical synthesis offers far lower production costs and vastly easier scale.
Concerns over GLP-1 muscle wasting are overstated and conflated with normal physiology, according to David Ricks. Any 50-pound weight reduction reduces structural muscle needed to ambulate. Furthermore, standard body scans classify tissue in a binary fashion as fat or non-fat. Marbled intramuscular fat and reduction in organ fat (such as liver fat in MASH) are often misclassified as lost muscle tissue rather than health improvements.
Standard pharmaceutical M&A playbook flushes acquired personnel and secondary pipeline assets to isolate lead candidates, which often later fail. Eli Lilly instead preserves acquired scientific teams and development baskets until proof of concept. Ricks notes that pharma acquirers cannot reliably pick which asset will generate value upfront, and keeping talent intact integrates vital scientific expertise into internal research leadership.
Current amyloid treatments like Kisunla face biological limits in early symptomatic Alzheimer's because tau pathology takes over later in disease progression. Eli Lilly's Trailblazer 3 trial investigates treating patients with amyloid biological hallmarks before symptoms appear. Ricks argues that amyloid intervention matters most upstream, which could redefine clinical efficacy and testing paradigms across neurology.
When pursuing a compelling biological target, Eli Lilly frequently backs all available therapeutic modalities at once—advancing internal pipelines while acquiring external competitors. Despite internal friction, Ricks notes that running parallel modalities lets pharma companies pick the winning molecule based on human clinical data rather than theoretical superiority, while broadening organizational scientific awareness.